Pulse Biosciences (PLSE) Common Equity (2015 - 2025)

Pulse Biosciences' Common Equity history runs 11 years deep, the most recent figure standing at $80.7 million for Q4 2025.

• On a quarterly basis, Common Equity fell 29.78% year-over-year to $80.7 million in Q4 2025; TTM through Dec 2025 was $80.7 million, a 29.78% decrease from a year earlier, with the FY2025 full-year figure at $80.7 million, down 29.78% from the prior year.
• Common Equity eased to $80.7 million in Q4 2025 per PLSE's latest filing, from $92.7 million in the prior quarter.
• Across five years, Common Equity topped out at $118.5 million in Q1 2025 and bottomed at -$10.7 million in Q1 2023.
• The 5-year median for Common Equity is $45.9 million (2021), against an average of $51.0 million.
• Biggest YoY gain for Common Equity was 2073.31% in 2023; the steepest drop was 151.29% in 2023.
• Year by year, Common Equity stood at $44.4 million in 2021, then sank by 105.07% to -$2.2 million in 2022, then soared by 2073.31% to $44.4 million in 2023, then soared by 158.93% to $114.9 million in 2024, then slipped by 29.78% to $80.7 million in 2025.
• Per Business Quant, the three latest PLSE Common Equity figures stand at $80.7 million (Q4 2025), $92.7 million (Q3 2025), and $104.5 million (Q2 2025).